Blog · DEC 19, 2023 · 3 min read
2023 in Indian Healthtech: Funding Cools, Fundamentals Matter
Indian healthtech funding fell roughly a third from its 2021 peak this year, and the companies still standing are the ones with real revenue.
2023 was the year the healthtech funding conversation in India changed shape. The 2021 peak, driven by pandemic-era digital health enthusiasm, produced a wave of well-funded consumer health apps chasing growth metrics that didn't translate into retained, paying users. By our count, total disclosed healthtech funding this year came in roughly a third below that peak, and the mix shifted hard toward later-stage, revenue-proven companies over early-stage bets on user acquisition.
What actually got funded
The rounds that closed this year skewed toward three categories: enterprise software selling into hospitals and pharma companies with existing budgets, diagnostics infrastructure with a clear reimbursement or B2B revenue path, and a smaller number of consumer plays that had already demonstrated retention rather than just installs. Pure-play consumer wellness and telemedicine apps, the biggest beneficiaries of 2021's enthusiasm, made up a visibly smaller share of the year's deal count.
The fundamentals investors actually checked
Term sheets this year came with harder questions attached: gross margin on the core product, not just the blended company average; customer concentration, since several 2021-era darlings turned out to have revenue clustered around one or two large accounts; and unit economics on customer acquisition that held up without discount-driven growth. None of this is exotic diligence, it's what should have been asked in 2021 too. It just wasn't, because capital was cheap enough that growth alone justified a valuation.
What this means going into 2024
Companies that spent 2021-2022 building genuine operational software, the unglamorous kind that saves a hospital or pharma company measurable money or time, are better positioned entering next year than companies that spent the same period on consumer acquisition. The market correction wasn't a healthtech-specific event, it mirrored software funding broadly. But healthcare's long sales cycles and regulatory friction mean the companies that survive a funding winter here tend to be the ones that were built assuming one would eventually come.